Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + empagliflozin + pioglitazone
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
"Group A" refers to an investigational triple combination therapy regimen consisting of semaglutide, empagliflozin, and pioglitazone. This regimen is being evaluated in a Phase 3 clinical trial (NCT06946628) led by Sun Yat-sen University for the treatment of newly diagnosed type 2 diabetes mellitus (T2DM). The strategy aims to achieve diabetes remission and preserve beta-cell function by combining three distinct mechanisms: GLP-1 receptor agonism (semaglutide), SGLT2 inhibition (empagliflozin), and PPAR-gamma activation (pioglitazone). This "early triple therapy" approach is compared against standard metformin-based stepwise treatment to determine its efficacy in improving glycemic control and achieving long-term remission.
- Other names
- early triple combination therapytriple combination therapy (semaglutide, empagliflozin, pioglitazone)
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)PPARA (Peroxisome proliferator-activated receptor alpha)SLC5A1 (Sodium Glucose Cotransporter 1)PPARG (Peroxisome proliferator-activated receptor gamma)GLP1R (GLP-1R)
Beyond the preview
Go deeper on semaglutide + empagliflozin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + empagliflozin + pioglitazone.